All In Biotech

Drug Trial Radar · NCT05633615

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

396

Planned (sponsor's estimate)

Start

Jun 12, 2023

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Genentech, Inc.
First posted
Dec 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a drug called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, and delivers vedotin to kill them. Chemotherapy drugs, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving mosunetuzumab and/or polatuzumab vedotin after chemotherapy and CAR T-cell therapy may be more effective at controlling or shrinking the cancer than not giving them.

Conditions

  • Diffuse Large B-Cell Lymphoma
  • Grade 3b Follicular Lymphoma
  • Primary Mediastinal (Thymic) Large B-Cell Lymphoma
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Transformed Follic Lymph to Diff Large B-Cell Lymphoma
  • Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma

Interventions

  • Axicabtagene CiloleucelBiological

    Given IV

  • Biospecimen CollectionProcedure

    Undergo collection of blood and tissue samples

  • Computed TomographyProcedure

    Undergo PET-CT or CT

  • CyclophosphamideDrug

    Given IV

  • FludarabineDrug

    Given IV

  • Lisocabtagene MaraleucelBiological

    Given IV

  • MosunetuzumabBiological

    Given IV

  • Patient ObservationOther

    Undergo observation

  • Polatuzumab VedotinDrug

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET-CT

  • TisagenlecleucelBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: From date of randomization to date of first observation of progressive disease or death due to any cause, assessed up to 2 years

Locations

95 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UCI Health Laguna Hills

    Laguna Hills, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • UCSF Medical Center-Parnassus

    San Francisco, California · Recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho · Recruiting

  • University of Illinois

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • Loyola University Medical Center

    Maywood, Illinois · Recruiting

  • University of Iowa/Holden Comprehensive Cancer Center

    Iowa City, Iowa · Recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • University of Kansas Cancer Center-Overland Park

    Overland Park, Kansas · Recruiting

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas · Recruiting

  • The James Graham Brown Cancer Center at University of Louisville

    Louisville, Kentucky · Recruiting

  • UofL Health Medical Center Northeast

    Louisville, Kentucky · Recruiting

  • LSU Health Baton Rouge-North Clinic

    Baton Rouge, Louisiana · Recruiting

  • Our Lady of the Lake Physician Group

    Baton Rouge, Louisiana · Recruiting

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland · Recruiting

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland · Recruiting

  • Bronson Battle Creek

    Battle Creek, Michigan · Recruiting

  • Henry Ford Macomb Hospital-Clinton Township

    Clinton Township, Michigan · Recruiting

  • Henry Ford Medical Center-Fairlane

    Dearborn, Michigan · Recruiting

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Weisberg Cancer Treatment Center

    Farmington Hills, Michigan · Recruiting

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    Grand Rapids, Michigan · Recruiting

  • Trinity Health Grand Rapids Hospital

    Grand Rapids, Michigan · Suspended

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.